Article
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Blood - 2 Mar 2023
Roas Maike, Vick Binje, Kasper Marc-André, Able Marina, Polzer Harald, Gerlach Marcus, Kremmer Elisabeth, Hecker Judith S, Schmitt Saskia, Stengl Andreas, Waller Verena, Hohmann Natascha, Festini Moreno, Ludwig Alexander, Rohrbacher Lisa, Herold Tobias, Subklewe Marion, Götze Katharina S, Hackenberger Christian P R, Schumacher Dominik, Helma-Smets Jonas, Jeremias Irmela, Leonhardt Heinrich, Spiekermann Karsten
Abstract excerpt
Fms-like tyrosine kinase 3 (FLT3) is often overexpressed or constitutively activated by internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations in acute myeloid leukemia (AML). Despite the use of receptor tyrosine kinase inhibitors (TKI) in FLT3-ITD-positive AML, the prognosis of patients is still poor, and further improvement of therapy is required. Targeting FLT3 independent of mutations by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.